PMD Psychemedics Corp.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Psychemedics Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (Nasdaq: PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Psychemedics common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of the conduct.

According to the complaint, following a January 31, 2017 press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and liable for millions in losses, the value of Psychemedics shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Psychemedics common stock purchased on or after February 28, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
09/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Psychemedics Corp.

 PRESS RELEASE

Psychemedics Releases 2025 Workforce Insights Report

Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...

 PRESS RELEASE

Psychemedics Named “Most Innovative Drug Testing Company of the Year”

Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...

 PRESS RELEASE

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced D...

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate’s or employee’s test results fall within a range o...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch